Books, Journals, New Media Section Editor: Harriet
S. Meyer, MD, Contributing Editor, JAMA; David H. Morse, MS, University
of Southern California, Norris Medical Library, Journal Review Editor.
Its title and subtitle accurately convey this book's message. This is
essentially a puff piece for Novartis, the Swiss pharmaceutical giant that
made such a splash with its introduction of Gleevec, the breakthrough drug
for chronic myelogenous leukemia (CML). Daniel Vasella, MD, chairman and CEO
of the company, with the help of professional writer Robert Slater, gives
us his version of how it all happened. And to hear him tell the story, the
new drug was primarily the product of wise corporate management (his) and
the contributions of a host of company scientists and technicians, whose work
Relman AS. Cancer Drug. JAMA. 2003;290(16):2194–2195. doi:10.1001/jama.290.16.2194
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: